Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

American Heart Journal

Volumn 144, Issue 6, 2002, Pages 1044-1051

  Olsson, Anders G ^a   Istad, Helge ^c   Luurila, Olavi ^e   Ose, Leiv ^d   Stender, Steen ^g   Tuomilehto, Jaakko ^f   Wiklund, Olov ^b   Southworth, Harry ^h   Pears, John ^h   Wilpshaar, J W ^h  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Theresegate Legesenter   (Norway)

^d Lipidklinikken   (Norway)

^e Lääkäriasemo KOE Oy   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSOMNIA; LIPID BLOOD LEVEL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036915307     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.128049     Document Type: Article

References (20)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
3. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
4. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-8.
5. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
6. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES) study. Am J Cardiol 1998;81:582-7.
7. Remmell PS, Gorder DD, Hall Y, et al. Assessing dietary adherence in Multiple Risk Factor Intervention Trial (MRFIT), I: Use of a dietary monitoring too. JAMA 1980;76:351-6.
8. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
9. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
10. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, 1-year study comparing safely and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
11. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-7.
12. Davidson M, McKenney J, Stein E, et al. Comparison of 1-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79:1475-81.
13. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-72.
14. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-56.
15. Farnier M, Portal J-J, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther 2000;5:27-32.
16. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs atorvastatin in patients with type IIA or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-75.
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1616-22.
18. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
19. Castelli WP, Anderson K. A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 1986;80:23-32.
20. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001;358:2026-33.